MAPT and Alzheimer disease: For example, Ondrejcak et al. (2018) suggested a postsynaptic action of oTau by showing that administrating intracerebroventricular injections, of either recombinant aggregated tau protein or tau protein isolated from human Alzheimer’s disease (AD) patients, inhibited hippocampal long-term potentiation (LTP) with no effect on paired-pulse ratio.